Top

Published in:

01-05-2022 | Fluorescence in Situ Hybridization | Original Article

Comparing the 2017 ASCO/CAP guideline for gastroesophageal adenocarcinoma surgical specimen to the 2018 ASCO/CAP guideline for breast cancer in assessing the HER2 status in primary mucinous ovarian carcinoma

Authors: Wan-Ru Chao, Ming-Yung Lee, Yi-Ju Lee, Gwo-Tarng Sheu, Chih-Ping Han

Published in: Virchows Archiv | Issue 5/2022

Abstract

The successful experiences of HER2 inhibitors in patients with HER2 ( +) breast cancer (BC) and advanced gastroesophageal adenocarcinoma (GEA) have encouraged us to continuously explore the HER2 status and its potential as a therapeutic target in primary mucinous ovarian carcinoma (mOC). Using 49 primary mOC samples, we compared the assay characteristics of HER2 status between both 2017 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) for GEA and 2018 ASCO/CAP for BC guideline recommendations. We demonstrated moderate to strong agreement between their HER2 IHC results (Weighted Kappa = 0.78) and perfect agreement between their HER2 FISH results (Kappa = 1.00). The overall concordance of non-equivocal HER2 IHC and HER2 FISH results was 97.56% (kappa = 0.93) by 2017 ASCO/CAP for GEA criteria and 100% (kappa = 1.00) by 2018 ASCO/CAP for BC criteria. The number (n = 8; 16.32%) of HER2 IHC equivocal (score + 2) by 2017 ASCO/CAP for GEA criteria was twofold higher than that (n = 4; 8.16%) by 2018 ASCO/CAP for BC criteria. Additionally, we identified one false-positive (FP) case (n = 1; 2.04%) that was HER2 IHC positive (score + 3), but HER2 FISH non-amplified result by the 2017 ASCO/CAP for GEA criteria. In conclusion, owing to the absence of FP/ FN and fewer equivocal cases of HER2 IHC, we recommend that the 2018 ASCO/CAP for BC are more appropriate than 2017 ASCO/CAP for GEA criteria in appraising the HER2 status in mOC and justifying the inclusion of eligible subjects for basket clinical trials of the newly developmental anti-HER2 treatments.

Morice P, Gouy S, Leary A (2019) Mucinous Ovarian Carcinoma. N Engl J Med 380:1256–1266. https://doi.org/10.1056/NEJMra1813254CrossRefPubMed

Chao WR, Lee MY, Lin WL, Koo CL, Sheu GT, Han CP (2014) Assessing the HER2 status in mucinous epithelial ovarian carcinoma on the basis of the 2013 ASCO/CAP guideline update. Am J Surg Pathol 38:1227–1234. https://doi.org/10.1097/PAS.0000000000000268CrossRefPubMed

McAlpine JN, Wiegand KC, Vang R et al (2009) Overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer 9:433CrossRef

Yan B, Choo SN, Mulyadi P et al (2011) Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours. J Clin Pathol 64:1097–1101CrossRef

Anglesio MS, Kommoss S, Tolcher MC et al (2013) Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol 229:111–120CrossRef

Chay WY, Chew SH, Ong WS et al (2013) HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer. PLoS One. 8:e61565CrossRef

Bartley AN, Washington MK, Colasacco C et al (2017) HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol 35(4):446–464. https://doi.org/10.1200/JCO.2016.69.4836CrossRefPubMed

Wolff AC, Hammond MEH, Allison KH et al (2018) Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 36:2105–2122. https://doi.org/10.1200/JCO.2018.77.8738CrossRefPubMed

English DP, Roque DM, Santin AD (2013) HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies. Mol Diagn Ther 17:85–99. https://doi.org/10.1007/s40291-013-0024-9CrossRefPubMedPubMedCentral

10.

Teplinsky E, Muggia F (2014) Targeting HER2 in ovarian and uterine cancers: challenges and future directions. Gynecol Oncol 135:364–370. https://doi.org/10.1016/j.ygyno.2014.09.003CrossRefPubMed

11.

Chao WR, Lee MY, Ruan A et al (2015) Assessment of HER2 Status Using Immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) Techniques in Mucinous Epithelial Ovarian Cancer: A Comprehensive Comparison between ToGA Biopsy Method and ToGA Surgical Specimen Method. PLoS ONE 10:e0142135. https://doi.org/10.1371/journal.pone.0142135CrossRefPubMedPubMedCentral

12.

Chen CK, Lee MY, Lin WL et al (2014) A qualitative study comparing the assay performance characteristics between the 2007 and the 2013 American Society for Clinical Oncology and College of American Pathologists HER2 scoring methods in mucinous epithelial ovarian cancer. Medicine (Baltimore) 93:e171. https://doi.org/10.1097/MD.0000000000000171CrossRef

13.

Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRef

14.

Wolff AC, Hammond ME, Hicks DG et al (2013) American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997–4013. https://doi.org/10.1200/JCO.2013.50.9984CrossRefPubMed

15.

Babaier A, Ghatage P (2020) Mucinous Cancer of the Ovary: Overview and Current Status. Diagnostics (Basel) 10:52. https://doi.org/10.3390/diagnostics10010052CrossRef

16.

Bang YJ, Van Cutsem E, Feyereislova A et al (2010) ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697. https://doi.org/10.1016/S0140-6736(10)61121-XCrossRefPubMed

17.

Gorringe KL, Cheasley D, Wakefield MJ et al (2020) Therapeutic options for mucinous ovarian carcinoma. Gynecol Oncol 156:552–560. https://doi.org/10.1016/j.ygyno.2019.12.015CrossRefPubMedPubMedCentral

18.

Jhaveri KL, Wang XV, Makker V et al (2019) Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Ann Oncol 30:1821–1830. https://doi.org/10.1093/annonc/mdz291CrossRefPubMedPubMedCentral

19.

Sun M, Shi H, Liu C, Liu J, Liu X, Sun Y (2014) Construction and evaluation of a novel humanized HER2-specific chimeric receptor. Breast Cancer Res 16:R61. https://doi.org/10.1186/bcr3674CrossRefPubMedPubMedCentral

20.

Lanitis E, Smith JB, Dangaj D et al (2014) A human ErbB2-specific T-cell receptor confers potent antitumor effector functions in genetically engineered primary cytotoxic lymphocytes. Hum Gene Ther 25:730–739. https://doi.org/10.1089/hum.2014.006CrossRefPubMedPubMedCentral

21.

Terlikowska KM, Dobrzycka B, Terlikowski SJ (2021) Chimeric Antigen Receptor Design and Efficacy in Ovarian Cancer Treatment. Int J Mol Sci 22:3495. https://doi.org/10.3390/ijms22073495CrossRefPubMedPubMedCentral

22.

Schepisi G, Casadei C, Toma I et al (2021) Immunotherapy and its development for gynecological (ovarian, endometrial and cervical) tumors: from immune checkpoint inhibitors to chimeric antigen receptor (CAR)-T cell therapy. Cancers (Basel) 13:840. https://doi.org/10.3390/cancers13040840CrossRef

Title: Comparing the 2017 ASCO/CAP guideline for gastroesophageal adenocarcinoma surgical specimen to the 2018 ASCO/CAP guideline for breast cancer in assessing the HER2 status in primary mucinous ovarian carcinoma
Authors: Wan-Ru Chao
Ming-Yung Lee
Yi-Ju Lee
Gwo-Tarng Sheu
Chih-Ping Han
Publication date: 01-05-2022
Publisher: Springer Berlin Heidelberg
Keywords: Fluorescence in Situ Hybridization
Breast Cancer
Ovarian Cancer
Ovarian Cancer
Breast Cancer
Published in: Virchows Archiv / Issue 5/2022
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-022-03285-9

At a glance: The STEP trials

Springer Medicine

Comparing the 2017 ASCO/CAP guideline for gastroesophageal adenocarcinoma surgical specimen to the 2018 ASCO/CAP guideline for breast cancer in assessing the HER2 status in primary mucinous ovarian carcinoma

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2022

T1 bladder carcinoma with variant histology: pathological features and clinical significance

Carcinosarcoma of the stomach: four cases that expand the morphologic spectrum of gastric cancer with a primitive phenotype

In this issue

Deeper sections reveal residual tumor cells in rectal cancer specimens diagnosed with pathological complete response following neoadjuvant treatment

Tumor progression by epithelial-mesenchymal transition in ARID1A- and SMARCA4-aberrant solid-type poorly differentiated gastric adenocarcinoma

Rapidly fatal SMARCA4-deficient undifferentiated sarcoma originating from hybrid hemosiderotic fibrolipomatous tumor/pleomorphic hyalinizing angiectatic tumor of the foot